The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib

被引：0
|
作者：
Francesco Grossi
Erika Rijavec
Maria Giovanna Dal Bello
Carlotta Defferrari
Annalisa Brianti
Giulia Barletta
Carlo Genova
Carmelina Murolo
Maurizio Cosso
Gabriella Fontanini
Laura Boldrini
Mauro Truini
Paolo Pronzato
机构：
[1] Istituto Nazionale per la Ricerca sul Cancro,S.S. Tumori Polmonari
[2] Istituto Nazionale per la Ricerca sul Cancro,S.C. Diagnostica per immagini ed interventistica oncologica
[3] Dipartimento di Chirurgia Università di Pisa,Sezione Anatomia Patologica
[4] Istituto Nazionale per la Ricerca sul Cancro,S.C. Anatomia e Citoistologia patologica
[5] Istituto Nazionale per la Ricerca sul Cancro,S.C. Oncologia Medica A
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Non-small-cell lung cancer; Gefitinib; Erlotinib; EGFR-TKI toxicity; EGFR mutation; K-ras mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1407 / 1412
页数：5
相关论文
共 50 条
  • [41] Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan
    Chang, Chia-Hao
    Lee, Chih-Hsin
    Ko, Jen-Chung
    Chang, Lih-Yu
    Lee, Ming-Chia
    Wang, Jann-Yuan
    Yu, Chong-Jen
    CANCER MEDICINE, 2017, 6 (07): : 1563 - 1572
  • [42] Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment: Is there a rationale for a clinical trial?
    Salesi, Nello
    Di Cocco, Barbara
    Calabretta, Francesca
    Ciorra, Alida Armida
    Cirino, Crescenzo
    Cauchi, Carolina
    Pistillucci, Giorgio
    Sciacca, Venerina
    Rossi, Rosalinda
    Veltri, Enzo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer
    Cappuzzo, F
    Magrini, E
    Ceresoli, GL
    Bartolini, S
    Rossi, E
    Ludovini, V
    Gregorc, V
    Ligorio, C
    Cancellieri, A
    Damiani, S
    Spreafico, A
    Paties, CT
    Lombardo, L
    Calandri, C
    Bellezza, G
    Tonato, M
    Crinò, L
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15): : 1133 - 1141
  • [44] Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
    C Gridelli
    P Maione
    V Castaldo
    A Rossi
    British Journal of Cancer, 2003, 89 : 1827 - 1829
  • [45] Gefitinib: A new antineoplastic for advanced non-small-cell lung cancer
    Cersosimo, RJ
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (09) : 889 - 898
  • [46] Erlotinib after Failure of Gefitinib Treatment of More Than 6 Months in Advanced Non-Small Cell Lung Cancer
    Kaira, Kyoichi
    Yamamoto, Nobuyuki
    ONKOLOGIE, 2012, 35 (1-2): : 8 - 9
  • [47] Erlotinib in patients with advanced non-small-cell lung cancer: a meta-analysis
    Gao, Hui
    Ding, Xin
    Wei, Dong
    Cheng, Peng
    Su, Xiaomei
    Liu, Huanyi
    Aziz, Fahad
    Wang, Daoyuan
    Zhang, Tao
    TRANSLATIONAL LUNG CANCER RESEARCH, 2012, 1 (02) : 129 - 144
  • [48] Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer
    Hotta, Katsuyuki
    Kiura, Katsuyuki
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (07) : 991 - 997
  • [49] Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
    Gridelli, C
    Maione, P
    Castaldo, V
    Rossi, A
    BRITISH JOURNAL OF CANCER, 2003, 89 (10) : 1827 - 1829
  • [50] Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer
    De Braud, F
    De Pas, T
    Spaggiari, L
    Veronesi, G
    Curigliano, G
    Noberasco, C
    Pelosi, G
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (06): : 461 - 462
12345